Healthcare systems are also predicted to face an additional $1.1 trillion burden due to climate-induced impacts (Quantifying the Impact of Climate Change on Human Health. World Economic Forum). Between 2030 and 2050, climate change is expected to cause approximately 250,000 additional deaths per year due to heat stress, malnutrition, malaria, and diarrhea (WHO).
Serving the Planet
our strategic pillars
We are determined to make firm commitments to protect the planet
We acknowledge the interdependence between human health and the health of the planet. We take climate actions by improving energy efficiency, using green energy and engaging suppliers. We transform the way we develop our medicines and packaging by working towards eco-design.
Fight climate change
As a global average, healthcare systems account for over 4% of CO2 emissions. For most industrialized nations, the figure is closer to 10% of national emissions (World Economic Forum). Drugs and medical devices are responsible for more than half of these emissions.
Did you know?
Our commitment
We will reduce our climate footprint in line with the Paris Agreement. This implies that we will reduce our emissions of both direct operations (scope 1 & 2) and indirect emissions (scope 3), as well as engage key suppliers to set decarbonization targets. We will also improve our business resilience through the management of climate-related physical and transition risks.
Group objectives
Scope 1&2 (direct operations):
Scope 3 (indirect emissions):
Where we are with our carbon footprint
We take action in four key areas to achieve our objectives:
Year on year, we increase the proportion of renewable energy in our overall energy mix. Currently, ten of our industrial facilities are equipped with photovoltaic panels that generate renewable electricity directly on site. Overall, ten industrial and R&D facilities are fully self-sufficient in renewable electricity (Arklow in Ireland, Toledo in Spain, Jacarepagua in Brazil, Anpharm in Poland, Tianjin in China, Sophyno in Russia, Symphogen in Denmark, our plants in Gidy and Bolbec in France and our research center in Budapest, Hungary).
54%
percentage of renewable electricity in the Group’s electricity consumption in 2024/2025
73%
of our industrial facilities are certified ISO 50001 or 14001 (Oril and Gidy in France, Arklow in Ireland, Anpharm in Poland, Toledo in Spain, Cairo in Egypt, Sophyno in Russia and Tianjin in China)
We require the suppliers involved with our brand-name medicine business to provide information regarding greenhouse gas emissions and systematically integrate climate data in assessments of companies responding to calls for tender.
In 2024/2025, 62% of intercontinental shipments were transported by sea and 38% by air. Compared with last year, this represents a significant increase in the proportion of sea freight and a significant reduction in air freight.
Part of the Group’s Scope 1 emissions are linked to the vehicles of its fleet, which are essential to our medical visitors. Servier is working to build an energy transition strategy for its vehicle fleet, adapted to the market characteristics of its various subsidiaries
The percentage of diesel vehicles in the Group’s fleet decreased from 34% in 2023/2024 to 23% in 2024/2025.
Protect nature
Nature has a limited capacity for adapting to the impacts of industrial production. Local ecosystems, as well as the planet as a whole, set boundaries for the levels of resources that can be extracted from nature, as well as the levels of substances that can be released back into nature. Pharmaceutical manufacturing is therefore faced with the need to modernize and transform to better align with the boundaries of nature.
Our commitment
The Servier Group is committed to protecting nature and reducing the adverse impact of its activities locally and globally. We are therefore building water stewardship across our sites. We take measures to save on the use of water, avoid water pollution and improve our waste management. We especially seek to reduce our footprint on local ecosystems in sites that have a significant local environmental impact.
Group objectives
Water reduction
Waste management
Our actions to protect nature
In 2024/2025 we achieve a 16% reduction in water consumption across all our industrial sites compared to 2021/2022.
This result was achieved by example thanks to:
Develop more sustainable medicines
The production of medicines involves use of chemicals and biologics to carry out research into the causes of disease to support discovery of new medicines in the manufacture of active pharmaceutical ingredients (APIs) and in the formulation of products. While APIs have positive effects when used in treatment, they often represent risks to health and nature if they are dispatched in the environment. Environmental considerations should be considered along the life cycle of product, from selection of raw materials, design of packaging, to manufacturing and logistic plans, until management of end of life of medicines with end users.
Drug manufacturing and the improper disposal of unused medicines can also add to the trace levels of pharmaceuticals in rivers, lakes, soils, and sometimes drinking water.
Our commitment
To deliver medicines that improve health outcomes and minimize the impact on the planet, we evaluate and aim to integrate environmental considerations along the entire product life cycle: raw material selection, synthesis route, packaging design, manufacturing processes, and controlling the release of chemicals and pharmaceuticals into the environment through the use of our medicines.
Harnessing Ecodesign to drive progress
Throughout the entire medicine value chain (from the R&D phase through to the product end of life, and including raw material procurement, manufacturing, logistics, distribution and use), we see Ecodesign as a keyway to drive progress. We aim to reduce the impact of our operations on the environment while constantly maintaining efficacy and therapeutic safety standards.
The Ecodesign program
Our Green Score tool seeks to integrate the principles of green chemistry and ecodesign in synthetic substance activities for our medicines. It is currently being deployed and will enable us to assess the environmental impact of 100% of our new industrial chemical synthetic substances.
By 2030, 100% of our brand-name medicines will integrate an ecodesign approach.
[1] Target for 2029/30, with 2021/22 as baseline year
[2] Emissions from direct purchasing (Raw Materials, Packaging, External Manufacturing) and Transport (200 suppliers), with 2023/24 as baseline year
[3] Suppliers covering 50% of emissions from Purchased Goods & Services (~500 suppliers, # of suppliers subject to changes depending on Biogaran)
[4] This objective covers Princeps manufacturing sites. A group objective will be defined at a later stage.